Aptinyx Inc., a clinical-stage biopharmaceutical company based in Evanston, Illinois, is making waves in the medical industry with its focus on developing and commercializing novel synthetic small molecules to address brain and nervous system disorders. The firm's flagship product, NYX-2925, is currently in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, with a separate Phase II/b trial underway to tackle fibromyalgia. Aptinyx Inc. is also working on NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator in a Phase II/b clinical trial to treat post-traumatic stress disorder, and NYX-458, an NMDAr modulator in a Phase II clinical study designed to target Parkinson's disease cognitive impairment. Allergan plc is one of the company's key collaborators, with a research agreement in place. Aptinyx Inc. was founded in 2015, and its cutting-edge research continues to make significant strides in addressing some of the most challenging medical conditions of our time.